Calprotectin I Serum as a Diagnostic Marker

Calprotectin I in Serum as a Diagnostic Marker of Pneumonia in Patients Hospitalised With Acute COPD Exacerbation

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03474484

Enrollment

113

Registered

2018-03-22

Start date

2018-04-03

Completion date

2018-09-14

Last updated

2018-09-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pulmonary Disease, Chronic Obstructive

Keywords

Biomarkers, Sensitivity and Specificity, Clinical Deterioration

Brief summary

Lower respiratory tract infection is the most common cause of acute exacerbations of chronic obstructive pulmonary disease (AECOPD). Patients diagnosed with pneumonia in addition to an AECOPD experience more severe clinical and laboratory disease manifestations, increase in-hospital morbidity and worse outcome. Clinicians have sought for new biomarkers that together with clinical assessments can improve the diagnostic accuracy of pneumonia in patients with AECOPD.The aim of the present study is to compare the accuracy of calprotectin with procalcitonin (PCT), C-reactive protein (CRP) and white blood cell count (WBC).

Interventions

None listed

Study design

Observational model

CASE_ONLY

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* clinically confirmed acute exacerbation of chronic obstructive pulmonary disorder (AECOPD) * COPD diagnosis previously confirmed by spirometry according to the GOLD criteria.

Exclusion criteria

* known malignant disease * bronchiectasis * chronic bacterial colonisation of the airways * treatment with an immunosuppressive drug or long-term treatment with antibiotics. * not examined with a chest X-ray at admission

Design outcomes

Primary

Measure	Time frame	Description
Calprotectin concentration in serum	Change in serum concentration from baseline to 48 hours	ELISA-kit (MRP8/14 ELISA)

Countries

Norway

Outcome results